1. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia
- Author
-
Wnukowski-Mtonga, P, Jayasinghe, S, Chiu, C, Macartney, K, Brotherton, J, Donovan, B ; https://orcid.org/0000-0001-8851-4126, Hall, M, Smith, DW, Peterson, K, Campbell-Lloyd, S, Selvey, C, Giles, M, Kaldor, J ; https://orcid.org/0000-0002-7639-4355, Marshall, H, Wnukowski-Mtonga, P, Jayasinghe, S, Chiu, C, Macartney, K, Brotherton, J, Donovan, B ; https://orcid.org/0000-0001-8851-4126, Hall, M, Smith, DW, Peterson, K, Campbell-Lloyd, S, Selvey, C, Giles, M, Kaldor, J ; https://orcid.org/0000-0002-7639-4355, and Marshall, H
- Abstract
The Australian Technical Advisory Group on Immunisation (ATAGI) updated recommendations on the use of human papillomavirus (HPV) vaccines in the Australian Immunisation Handbook in 2018, regarding the use of the recently available 9-valent (9vHPV) vaccine, Gardasil 9, and a 2-dose schedule for young adolescents for HPV vaccines. This report provides an overview of the relevant scientific evidence that underpinned these updated recommendations. The 9vHPV vaccine includes 5 HPV types (HPV 31, 33, 45, 52 and 58) additional to the 4 that are also covered by the 4vHPV (Gardasil) vaccine (HPV 6,11,16,18). Accordingly, the 9vHPV vaccine is expected to prevent an additional 15% of cervical cancers and up to 20% of other HPV-related cancers. Non-inferior antibody responses after two 9vHPV vaccine doses given 6-12 months apart in girls and boys aged 9-14 years compared to women aged 16-26 years after three doses support the 2-dose schedule for adolescents of this age group. In clinical trials 9vHPV vaccine was well-tolerated with a similar safety profile to 4vHPV vaccine. The switch to 9vHPV vaccine and a 2-dose schedule is anticipated to improve public acceptability of the program and reduce HPV-related disease in the long-term.
- Published
- 2020